81 related articles for article (PubMed ID: 38429886)
1. Clinical outcomes and biomarker exploration of first-line PD-1 inhibitors plus chemotherapy in patients with low PD-L1-expressing of gastric or gastroesophageal junction adenocarcinoma.
Sun YT; Lu SX; Lai MY; Yang X; Guan WL; Yang LQ; Li YH; Wang FH; Yang DJ; Qiu MZ
Cancer Immunol Immunother; 2024 Jun; 73(8):144. PubMed ID: 38832979
[TBL] [Abstract][Full Text] [Related]
2. Clinical application of targeted tumour sequencing tests for detecting ERBB2 amplification and optimizing anti-HER2 therapy in gastric cancer.
Ichikawa H; Usui K; Aizawa M; Shimada Y; Muneoka Y; Kano Y; Sugai M; Moro K; Hirose Y; Miura K; Sakata J; Yabusaki H; Nakagawa S; Kawasaki T; Umezu H; Okuda S; Wakai T
BMC Cancer; 2024 Jun; 24(1):719. PubMed ID: 38862927
[TBL] [Abstract][Full Text] [Related]
3. Molecular Landscape and Clinical Implication of CCNE1-amplified Esophagogastric Cancer.
Rustgi N; Wu S; Samec T; Walker P; Xiu J; Lou E; Goel S; Saeed A; Moy RH
Cancer Res Commun; 2024 Jun; 4(6):1399-1409. PubMed ID: 38717153
[TBL] [Abstract][Full Text] [Related]
4. Retrospective Study of Claudin 18 Isoform 2 Prevalence and Prognostic Association in Gastric and Gastroesophageal Junction Adenocarcinoma.
Waters R; Sewastjanow-Silva M; Yamashita K; Abdelhakeem A; Iwata KK; Moran D; Elsouda D; Guerrero A; Pizzi M; Vicentini ER; Shanbhag N; Ta A; Chatterjee D; Ajani JA
JCO Precis Oncol; 2024 May; 8():e2300543. PubMed ID: 38781542
[TBL] [Abstract][Full Text] [Related]
5. Genetic Predictors of Response to Systemic Therapy in Esophagogastric Cancer.
Janjigian YY; Sanchez-Vega F; Jonsson P; Chatila WK; Hechtman JF; Ku GY; Riches JC; Tuvy Y; Kundra R; Bouvier N; Vakiani E; Gao J; Heins ZJ; Gross BE; Kelsen DP; Zhang L; Strong VE; Schattner M; Gerdes H; Coit DG; Bains M; Stadler ZK; Rusch VW; Jones DR; Molena D; Shia J; Robson ME; Capanu M; Middha S; Zehir A; Hyman DM; Scaltriti M; Ladanyi M; Rosen N; Ilson DH; Berger MF; Tang L; Taylor BS; Solit DB; Schultz N
Cancer Discov; 2018 Jan; 8(1):49-58. PubMed ID: 29122777
[TBL] [Abstract][Full Text] [Related]
6. Immune checkpoint markers and tumour mutation burden in Wilms tumour: a study of 59 cases.
Mattis AJ; Chen JF; Gonzalez IA; Rais R; Dehner LP; Pfeifer J; He M
Pathology; 2024 May; ():. PubMed ID: 38879422
[TBL] [Abstract][Full Text] [Related]
7. Fetal gut cell-like differentiation in esophageal adenocarcinoma defines a rare tumor subtype with therapeutically relevant claudin-6 positivity and SWI/SNF gene alteration.
Kraemer M; Zander T; Alakus H; Buettner R; Lyu SI; Simon AG; Schroeder W; Bruns CJ; Quaas A
Sci Rep; 2024 Jun; 14(1):13474. PubMed ID: 38866822
[TBL] [Abstract][Full Text] [Related]
8. Evidence to Date on the Therapeutic Potential of Zolbetuximab in Advanced Gastroesophageal Adenocarcinoma.
Rogers JE; Ajani J
Curr Oncol; 2024 Feb; 31(2):769-777. PubMed ID: 38392051
[TBL] [Abstract][Full Text] [Related]
9. State of the art and upcoming trends in claudin-directed therapies in gastrointestinal malignancies.
Rogers JE; Ajani JA
Curr Opin Oncol; 2024 Jul; 36(4):308-312. PubMed ID: 38726797
[TBL] [Abstract][Full Text] [Related]
10. Evolution of predictive and prognostic biomarkers in the treatment of advanced gastric cancer.
Myer NM; Shitara K; Chung HC; Lordick F; Kelly RJ; Szabo Z; Cao ZA; Leong S; Ilson DH; Weichert W
J Cancer Res Clin Oncol; 2022 Aug; 148(8):2023-2043. PubMed ID: 35551464
[TBL] [Abstract][Full Text] [Related]
11. Association of CLDN18 Protein Expression with Clinicopathological Features and Prognosis in Advanced Gastric and Gastroesophageal Junction Adenocarcinomas.
Pellino A; Brignola S; Riello E; Niero M; Murgioni S; Guido M; Nappo F; Businello G; Sbaraglia M; Bergamo F; Spolverato G; Pucciarelli S; Merigliano S; Pilati P; Cavallin F; Realdon S; Farinati F; Dei Tos AP; Zagonel V; Lonardi S; Loupakis F; Fassan M
J Pers Med; 2021 Oct; 11(11):. PubMed ID: 34834447
[TBL] [Abstract][Full Text] [Related]
12. Claudin-18.2 testing and its impact in the therapeutic management of patients with gastric and gastroesophageal adenocarcinomas: A literature review with expert opinion.
Angerilli V; Ghelardi F; Nappo F; Grillo F; Parente P; Lonardi S; Luchini C; Pietrantonio F; Ugolini C; Vanoli A; Fassan M
Pathol Res Pract; 2024 Feb; 254():155145. PubMed ID: 38277741
[TBL] [Abstract][Full Text] [Related]
13. The Use of Epidermal Growth Factor Receptor Type 2-Targeting Tyrosine Kinase Inhibitors in the Management of Epidermal Growth Factor Receptor Type 2-Positive Gastric Cancer: A Narrative Review.
AlMazmomy AM; Al-Hayani MM; Alomari M; Bazi AG
Cureus; 2019 Dec; 11(12):e6295. PubMed ID: 31938588
[TBL] [Abstract][Full Text] [Related]
14. Whole-transcriptome sequencing in advanced gastric or gastroesophageal cancer: A deep dive into its clinical potential.
Hashimoto T; Nakamura Y; Mishima S; Nakayama I; Kotani D; Kawazoe A; Kuboki Y; Bando H; Kojima T; Iida N; Shibuki T; Imai M; Fujisawa T; Nagamine M; Sakamoto N; Kuwata T; Yoshino T; Shitara K
Cancer Sci; 2024 May; 115(5):1622-1633. PubMed ID: 38429886
[TBL] [Abstract][Full Text] [Related]
15. Comprehensive clinical and molecular characterization of claudin 18.2 expression in advanced gastric or gastroesophageal junction cancer.
Kubota Y; Kawazoe A; Mishima S; Nakamura Y; Kotani D; Kuboki Y; Bando H; Kojima T; Doi T; Yoshino T; Kuwata T; Shitara K
ESMO Open; 2023 Feb; 8(1):100762. PubMed ID: 36610262
[TBL] [Abstract][Full Text] [Related]
16. Clinical Significance of HER2 Overexpression in Gastric and Gastroesophageal Junction Cancers.
Baykara M; Benekli M; Ekinci O; Irkkan SC; Karaca H; Demirci U; Akinci MB; Unal OU; Dane F; Turkoz FP; Balakan O; Eser EP; Ozturk SC; Ozkan M; Oksuzoglu B; Sevinc A; Demir N; Harputluoglu H; Yalcin B; Coskun U; Uner A; Ozet A; Buyukberber S;
J Gastrointest Surg; 2015 Sep; 19(9):1565-71. PubMed ID: 26179664
[TBL] [Abstract][Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]